Medpace Holdings, Inc. MEDP 75.4
Health Care · NASDAQ · Data as of 2026-10-22
Medpace Holdings, Inc. (MEDP) has delivered +22.8% annualized revenue growth, +41.8% earnings growth, and n/a dividend growth over 10 years of data. Ranked #173 of 1968 stocks overall and #15 of 260 in the Health Care sector by Steady Score.
About Medpace Holdings, Inc.
Company Overview
Medpace provides clinical research services that help pharmaceutical, biotechnology and medical-device companies develop new products. It plans and manages clinical trials from early through post-marketing stages, coordinating investigators, patient data, regulatory work, safety monitoring and submissions. Supporting capabilities include central laboratories, imaging, electrocardiography, bioanalytical testing and clinical pharmacology, allowing sponsors to use one provider across many trial activities.
Read more
Business Model & Revenue
Medpace earns service revenue under contracts for individual clinical-development projects. Fees reflect the work performed, staffing, milestones and trial progress; reimbursed travel, investigator payments and other pass-through costs are also included in reported revenue. Projects may run for several years, but sponsors can change scope or cancel them. New business awards, backlog conversion, study starts, patient enrollment and employee capacity shape revenue over time.
Key Facts & Market Position
The company uses a full-service model, combining trial management with laboratories and specialized diagnostic support rather than supplying only one function. It focuses on small and mid-sized biopharmaceutical sponsors as well as larger customers and works across therapeutic areas. Scientific expertise, regulatory execution and reliable site coordination are central, while project concentration and cancellations can affect utilization.